Prot# IDN-6556-12: A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Nonalcoholic Steatohepatitis (NASH) Fibrosis

Project: Research project

Project Details

StatusFinished
Effective start/end date5/10/165/10/19

Funding

  • PPD Development (Prot# IDN-6556-12)
  • Conatus Pharmaceuticals Inc. (Prot# IDN-6556-12)